With the purchase of Organon & Co., billionaire Dilip Shanghvi's Sun Pharmaceutical Industries' annual revenue will more than double to $12.4 billion and make it one of the world’s top 25 drugmakers.

Speculation about succession at Sun Pharmaceutical Industries, India’s most valuable drug maker, was put to rest this year when its billionaire founder, Dilip Shanghvi, made some changes at the top.

Dilip Shanghvi & Kirti Ganorkar (From left to right) NEW DELHI: Sun Pharma announced that its India business head, Kirti Ganorkar will be elevated as the company’s managing director to succeed the founder, Dilip Shanghvi, effective September 1. The move is part of a structured and forward-looking succession planning process at Sun Pharma, underscoring the organisation’s commitment to leadership continuity and strategic governance, a company statement said. Ganorkar, who has been heading the India business since June 2019, will now lead the company’s entire business including all its geographies, and functions.

Dilip Shanghvi, an Indian billionaire and founder of Sun Pharmaceuticals, transformed a modest investment of Rs 10,000 into a global pharmaceutical giant. Established in 1982, the company achieved significant growth through strategic acquisitions and innovation, with current revenues of $5.4 billion and a net worth of Rs 2,74,000 crore.

Sun Pharmaceutical Industries Ltd will continue to focus on its specialty products in FY26, which contributed to India's largest drugmaker's growth last fiscal. The company plans to invest an additional $100 million on the commercialization of its new specialty product pipeline in the US, chairman and managing director Dilip Shanghvi said in an earnings call on Thursday. Also Read | …

Have a look at the biography, education and net worth of Vidhi Shanghvi Vidhi Shanghvi, the daughter of Dilip Shanghvi who is the richest healthcare billionaire in India, is a major player in Sun Pharmaceutical Industries, a healthcare conglomerate worth Rs 4.35 lakh crore. A world leader in the pharmaceutical sector, Sun Pharmaceutical Industries Limited owned by the father of Vidhi Shanghvi is renowned for its wide distribution and superior medications.

Nonostante la rupia in calo e le tensioni commerciali, 30 nuovi miliardari portano a un record la ricchezza indiana complessiva

Mumbai: Sun Pharmaceutical Industries has decided to proceed with a binding offer of $12 billion for Organon & Co, taking the company to the final stages of its most ambitious overseas acquisition bid as it looks to become a branded and innovative drug-making powerhouse, said people in the know. Mumbai-based Sun, led by billionaire founder Dilip Shanghvi, 70, has completed detailed due diligence that lasted over three months and is now finalising a financing package before submission of a firm offer in the coming weeks. At least three global banks were mandated last week to back the bid, which will be the largest global M&A involving an Indian pharma major if it goes ahead.

Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and oncology company Checkpoint Therapeutics for $355 million to bolster the Mumbai-based company’s drug portfolio.

Sun Pharmaceutical Industries has appointed Kirti Ganorkar as its new managing director, effective September 1. Dilip Shanghvi, the current managing director, will remain with the company as executive director and chair of the board.

Dilip Shanghvi, Founder and Managing Director of Sun Pharmaceutical Industries, has indicated potential plans to segment the company's operations into distinct verticals. This strategic consideration emerges as the US proposes a 25 per cent tariff on pharmaceutical imports, prompting Sun Pharma to evaluate its business structure and market strategies.

Sun Pharmaceutical Industries Ltd’s India business head Kirti Ganorkar will succeed founder Dilip Shanghvi as managing director as India’s largest drugmaker announced a major leadership rejig on Friday. Ganorkar will take on his new role effective 1 September 2025, the company said in a release. Shanghvi will continue on as executive chairman to chair the board, and focus on its specialty portfolio and shaping the company’s long-term strategy, it said.